GlassScriptPhysician profile
Noel T Nivera
NPI 1124034400
$8,480.13
in general payments reported to CMS, 2019-2025
33 companies · $1,155 in 2025
The $1,155 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $2,536 · 2021: $1,214 · 2022: $992 · 2023: $845 · 2024: $812 · 2025: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,812.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,054.11 | 2019-2025 | Voyxact |
| Vifor Pharma, INC. | $608.13 | 2019-2023 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $601.77 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Fresenius USA Marketing, INC. | $530.56 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $513.00 | 2021-2025 | |
| Arbor Pharmaceuticals, INC. | $453.39 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $427.66 | 2021-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $423.65 | 2019-2025 | Rayaldee |
| Amgen INC. | $347.47 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.12 | 2024-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $246.04 | 2020-2024 | Acthar |
| Calliditas Therapeutics US INC. | $234.76 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $202.50 | 2019-2025 | Jynarque |
| Mallinckrodt Enterprises LLC | $185.94 | 2019 | |
| Amarin Pharma, INC. | $169.77 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $154.91 | 2023-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $153.15 | 2021-2025 | Benlysta, Jesduvroq, Arexvy |
| Novo Nordisk INC | $136.41 | 2023-2025 | Ozempic, Wegovy |
| Horizon Therapeutics Plc | $131.62 | 2020-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $126.39 | 2022-2025 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $113.29 | 2019-2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $83.86 | 2024-2025 | |
| Daiichi Sankyo INC. | $75.49 | 2019-2023 | Injectafer |
| Lilly USA, LLC | $65.08 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Travere Therapeutics, INC. | $32.92 | 2025 | |
| Strongbridge US INC. | $29.80 | 2019 | |
| Azurity Pharmaceuticals, INC. | $28.41 | 2023-2025 | Edarbi, Edarbi |
| Scpharmaceuticals INC. | $25.40 | 2025 | |
| Biomerieux INC | $15.86 | 2020 | |
| Lundbeck LLC | $14.90 | 2020 | |
| Baxter Healthcare | $14.48 | 2019 | |
| Corcept Therapeutics | $14.11 | 2023 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noel Nivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.